SI3529262T1 - Postopki za spodbujanje odgovora T-celic - Google Patents

Postopki za spodbujanje odgovora T-celic

Info

Publication number
SI3529262T1
SI3529262T1 SI201730876T SI201730876T SI3529262T1 SI 3529262 T1 SI3529262 T1 SI 3529262T1 SI 201730876 T SI201730876 T SI 201730876T SI 201730876 T SI201730876 T SI 201730876T SI 3529262 T1 SI3529262 T1 SI 3529262T1
Authority
SI
Slovenia
Prior art keywords
promoting
methods
cells response
cells
response
Prior art date
Application number
SI201730876T
Other languages
English (en)
Slovenian (sl)
Inventor
Elise Chiffoleau
Geraldine Teppaz
Nicolas Poirier
Bernard Vanhove
Vanessa Gauttier
Original Assignee
Inserm - Institut National De La Sante Et De La Recherche Medicale
Universite De Nantes
Ose Immunotherapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm - Institut National De La Sante Et De La Recherche Medicale, Universite De Nantes, Ose Immunotherapeutics filed Critical Inserm - Institut National De La Sante Et De La Recherche Medicale
Publication of SI3529262T1 publication Critical patent/SI3529262T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201730876T 2016-10-21 2017-10-20 Postopki za spodbujanje odgovora T-celic SI3529262T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16306381 2016-10-21
EP17305988 2017-07-24
EP17797066.2A EP3529262B1 (en) 2016-10-21 2017-10-20 Methods for promoting t cells response
PCT/EP2017/076911 WO2018073440A1 (en) 2016-10-21 2017-10-20 Methods for promoting t cells response

Publications (1)

Publication Number Publication Date
SI3529262T1 true SI3529262T1 (sl) 2021-12-31

Family

ID=60293924

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201730876T SI3529262T1 (sl) 2016-10-21 2017-10-20 Postopki za spodbujanje odgovora T-celic

Country Status (21)

Country Link
US (3) US11365257B2 (enExample)
EP (2) EP3529262B1 (enExample)
JP (2) JP7032396B6 (enExample)
KR (1) KR102646708B1 (enExample)
CN (1) CN110291102A (enExample)
AU (1) AU2017345286B2 (enExample)
CA (1) CA3039348C (enExample)
CY (1) CY1124584T1 (enExample)
DK (1) DK3529262T3 (enExample)
ES (2) ES2978486T3 (enExample)
HR (1) HRP20211544T1 (enExample)
HU (1) HUE056016T2 (enExample)
IL (1) IL266111B (enExample)
LT (1) LT3529262T (enExample)
MA (1) MA46570B1 (enExample)
MD (1) MD3529262T2 (enExample)
PL (1) PL3529262T3 (enExample)
RS (1) RS62463B1 (enExample)
SI (1) SI3529262T1 (enExample)
SM (1) SMT202100555T1 (enExample)
WO (1) WO2018073440A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100555T1 (it) * 2016-10-21 2021-11-12 Inst Nat Sante Rech Med Metodi per promuovere la risposta di cellule t
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
EP4069372A1 (en) * 2019-12-05 2022-10-12 Ose Immunotherapeutics Anti-clec-1a antibodies and antigen-binding fragment thereof
CN113156140A (zh) * 2021-03-05 2021-07-23 青岛大学附属医院 C型凝集素样受体-1作为真菌性角膜炎的治疗标志物的应用
KR20240019295A (ko) 2021-06-08 2024-02-14 오제 이뮈노테라프틱스 인간화 항-clec-1a 항체 및 이의 항원 결합 단편 및 이의 모방체
US20250026839A1 (en) * 2021-11-09 2025-01-23 Ose Immunotherapeutics Identification of CLEC-1 Ligand and Uses Thereof
EP4565607A1 (en) 2022-08-01 2025-06-11 Ose Immunotherapeutics Heterodimeric fc-clec-1 fusion molecule and uses thereof
WO2025032213A1 (en) 2023-08-10 2025-02-13 Ose Immunotherapeutics Identification of hla-dra as a ligand of clec-1 and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5618829A (en) 1993-01-28 1997-04-08 Mitsubishi Chemical Corporation Tyrosine kinase inhibitors and benzoylacrylamide derivatives
CA2167153A1 (en) 1993-07-15 1995-01-26 Caroline Joy Springer Prodrugs of protein tyrosine kinase inhibitors
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
CN100503580C (zh) 1996-04-12 2009-06-24 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
US6740665B1 (en) 1999-02-10 2004-05-25 Ramachandran Murali Tyrosine kinase inhibitors and methods of using the same
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6329380B1 (en) 1999-06-30 2001-12-11 Merck & Co., Inc. SRC kinase inhibitor compounds
WO2001000214A1 (en) 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
EP1206265B1 (en) 1999-06-30 2003-11-12 Merck & Co., Inc. Src kinase inhibitor compounds
MXPA02002559A (es) 1999-09-10 2002-07-30 Merck & Co Inc Inhibidores de tirosina cinasa.
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2001029025A2 (en) 1999-10-19 2001-04-26 Merck & Co., Inc. Tyrosine kinase inhibitors
AU778042B2 (en) 1999-10-19 2004-11-11 Merck & Co., Inc. Tyrosine kinase inhibitors
JP5007007B2 (ja) * 1999-11-15 2012-08-22 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE316088T1 (de) 2001-06-22 2006-02-15 Merck & Co Inc Tyrosin-kinase inhibitoren
US6958340B2 (en) 2001-08-01 2005-10-25 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003020276A1 (en) 2001-08-30 2003-03-13 Merck & Co., Inc. Tyrosine kinase inhibitors
US8246959B1 (en) 2003-08-01 2012-08-21 University Of Washington Dendritic cell-associated lectin-like molecules, compositions and methods of use
US7908091B2 (en) 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
CA2717656A1 (en) * 2007-02-23 2008-08-28 Baylor Research Institute Activation of human antigen-presenting cells through clec-6
WO2011105424A1 (ja) * 2010-02-23 2011-09-01 国立大学法人東京大学 樹状細胞免疫受容体刺激剤
BR112017000939A2 (pt) * 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
SMT202100555T1 (it) 2016-10-21 2021-11-12 Inst Nat Sante Rech Med Metodi per promuovere la risposta di cellule t

Also Published As

Publication number Publication date
SMT202100555T1 (it) 2021-11-12
US12091464B2 (en) 2024-09-17
IL266111A (en) 2019-06-30
AU2017345286B2 (en) 2023-08-03
EP3529262B1 (en) 2021-07-21
PL3529262T3 (pl) 2021-12-27
JP7404418B2 (ja) 2023-12-25
JP7404418B6 (ja) 2024-01-26
RS62463B1 (sr) 2021-11-30
HUE056016T2 (hu) 2022-01-28
CA3039348A1 (en) 2018-04-26
MA46570B1 (fr) 2021-10-29
US20220281983A1 (en) 2022-09-08
JP7032396B2 (ja) 2022-03-08
IL266111B (en) 2022-09-01
AU2017345286A1 (en) 2019-04-18
HRP20211544T1 (hr) 2022-01-07
LT3529262T (lt) 2021-11-10
JP2022065159A (ja) 2022-04-26
CY1124584T1 (el) 2022-07-22
US20190309075A1 (en) 2019-10-10
MA46570A (fr) 2021-03-31
EP3529262A1 (en) 2019-08-28
JP2020503252A (ja) 2020-01-30
DK3529262T3 (da) 2021-09-20
US11365257B2 (en) 2022-06-21
KR102646708B1 (ko) 2024-03-12
MD3529262T2 (ro) 2022-01-31
KR20190068605A (ko) 2019-06-18
JP7032396B6 (ja) 2022-03-22
WO2018073440A1 (en) 2018-04-26
EP3950709B1 (en) 2024-02-14
ES2978486T3 (es) 2024-09-13
CA3039348C (en) 2023-09-05
CN110291102A (zh) 2019-09-27
ES2883678T3 (es) 2021-12-09
US20240400695A1 (en) 2024-12-05
EP3950709A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
IL274903A (en) cell
ZA201707334B (en) Cell
GB201610515D0 (en) Cell
GB201611982D0 (en) Cell culture
GB201507368D0 (en) Cell
GB201503500D0 (en) Cell
GB201514874D0 (en) Cell
GB201518817D0 (en) Cell
GB201621889D0 (en) Cell
GB201522097D0 (en) Cells
IL266111A (en) Methods for inducing a t-cell response
GB201616238D0 (en) Modified T cells
GB201603372D0 (en) Cell
ZA201900891B (en) B-cell-mimetic cells
GB201609604D0 (en) Cell
GB201617716D0 (en) Cell
PL3287521T3 (pl) Hodowla komórkowa
PL3149792T3 (pl) Ogniwo litowo-siarkowe
PL3560023T3 (pl) Elektrolit do baterii litowo-jonowych
GB201604427D0 (en) Modified cell
PT3529262T (pt) Métodos para promover resposta de células t
GB201617690D0 (en) Advanced solid biofuels
SG10202010002RA (en) Cell culture
GB201410934D0 (en) T cell
GB201507816D0 (en) Cell